Surgery Partners (SGRY) director receives 34,364 restricted stock awards

Q: Was Blair E. Hendrix’s Surgery Partners (SGRY) transaction an open-market purchase?

No. The transaction for Blair E. Hendrix is described as a grant or award acquisition of 34,364 restricted stock awards, not an open-market purchase. The shares were awarded at a reported value of $14.55 per share as part of equity compensation.

Q: What type of security did Blair E. Hendrix receive from Surgery Partners (SGRY)?

Blair E. Hendrix received restricted stock awards (RSAs) of Surgery Partners common stock. These RSAs total 34,364 shares , are valued at $14.55 per share , and vest in three equal annual installments beginning one year after the June 18, 2026 grant date.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

HENDRIX BLAIR E reported acquisition or exercise transactions in this Form 4 filing.

Surgery Partners, Inc. director Blair E. Hendrix received a grant of 34,364 restricted stock awards of common stock on June 18, 2026 at $14.55 per share. These RSAs vest in three equal annual installments starting one year after the grant. After this award, Hendrix directly holds 52,895 shares of common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider HENDRIX BLAIR E

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	34,364	$14.55	$500K

Holdings After Transaction: Common Stock — 52,895 shares (Direct)

Footnotes (1)

[object Object]

Key Figures

Restricted stock awards granted: 34,364 shares Grant price per share: $14.55 per share Shares held after transaction: 52,895 shares +1 more

4 metrics

Restricted stock awards granted 34,364 shares RSAs of common stock granted to Blair E. Hendrix on June 18, 2026

Grant price per share $14.55 per share Reported per-share value for the June 18, 2026 restricted stock awards

Shares held after transaction 52,895 shares Total direct holdings of Blair E. Hendrix after the grant

Vesting installments 3 annual installments RSAs vest in three equal annual installments beginning on the first anniversary of the Grant Date

Key Terms

restricted stock awards ("RSAs"), Grant Date, vest in three equal annual installments

3 terms

restricted stock awards ("RSAs") financial

"Represents restricted stock awards ("RSAs") granted to the reporting person"

Grant Date financial

"granted to the reporting person on June 18, 2026 (the "Grant Date")"

The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.

vest in three equal annual installments financial

"The RSAs vest in three equal annual installments beginning on the first anniversary"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/14/2026 - 05:07 PM Accepted by SEC EDGAR 07/14/2026 - 05:07 PM

FAQ

What insider transaction did Surgery Partners (SGRY) report for Blair E. Hendrix?

Surgery Partners reported that director Blair E. Hendrix received a grant of 34,364 restricted stock awards of common stock on June 18, 2026 at $14.55 per share. This equity grant represents an acquisition of shares as part of his director compensation.

How many Surgery Partners (SGRY) shares does Blair E. Hendrix hold after this grant?

Following the June 18, 2026 grant, Blair E. Hendrix directly holds 52,895 shares of Surgery Partners common stock. This figure includes the newly granted 34,364 restricted stock awards, which will vest over time according to the stated vesting schedule.

What is the vesting schedule for Blair E. Hendrix’s Surgery Partners (SGRY) restricted stock awards?

The 34,364 restricted stock awards granted to Blair E. Hendrix vest in three equal annual installments. Vesting begins on the first anniversary of the June 18, 2026 grant date, meaning one-third of the award vests each year over three years.

Was Blair E. Hendrix’s Surgery Partners (SGRY) transaction an open-market purchase?

No. The transaction for Blair E. Hendrix is described as a grant or award acquisition of 34,364 restricted stock awards, not an open-market purchase. The shares were awarded at a reported value of $14.55 per share as part of equity compensation.

Did the Surgery Partners (SGRY) report show any stock sales or option exercises for Blair E. Hendrix?

No sales or option exercises were reported for Blair E. Hendrix. The Form 4 data reflects only a single acquisition of 34,364 restricted stock awards, with no derivative transactions, gifts, or dispositions indicated in the summarized transaction counts.

What type of security did Blair E. Hendrix receive from Surgery Partners (SGRY)?

Blair E. Hendrix received restricted stock awards (RSAs) of Surgery Partners common stock. These RSAs total 34,364 shares, are valued at $14.55 per share, and vest in three equal annual installments beginning one year after the June 18, 2026 grant date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HENDRIX BLAIR E

(Last)

(First)

(Middle)

200 CLARENDON STREET

(Street)

BOSTON

MASSACHUSETTS

02116

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Surgery Partners, Inc. [ SGRY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/18/2026		A		34,364⁽¹⁾	A	$14.55	52,895	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents restricted stock awards ("RSAs") granted to the reporting person on June 18, 2026 (the "Grant Date"). The RSAs vest in three equal annual installments beginning on the first anniversary of the Grant Date.

Remarks:

	/s/ Blair E. Hendrix	07/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR